Wikipedia

Hallucinogen persisting perception disorder

Hallucinogen persisting perception disorder (HPPD) is a non-psychotic disorder in which a person experiences apparent lasting or persistent visual hallucinations or perceptual distortions after using drugs,[1] including but not limited to psychedelics, dissociatives, entactogens, tetrahydrocannabinol (THC), and SSRIs.[2][3] Despite being designated as a hallucinogen-specific disorder, the specific contributory role of psychedelic drugs is unknown.

Hallucinogen persisting perception disorder
A visual simulation of HPPD, often referred to as visual snow.
SpecialtyPsychiatry
SymptomsVisual disturbance
Types
  • Type I: brief, random flashbacks
  • Type II: chronic, long-term, and severe form
CausesPrimarily associated with the use of psychedelic substances
Prognosis
  • Type I: may resolve within months to years
  • Type II: considered lifelong

The hallucinations and perceptual changes consist of, but are not limited to, visual snow, trails and after images (palinopsia), light fractals on flat surfaces, intensified colors, altered motion perception, pareidolia, micropsia, and macropsia.[3] People who have never previously taken drugs have also reported some symptoms associated with HPPD (such as floaters and visual snow).[4][5]

HPPD is a DSM-5 diagnosis with diagnostic code 292.89 (F16.983).[6] For the diagnosis to be made, other psychological, psychiatric, or neurological conditions must be ruled out and it must cause distress in everyday life.[6] In the ICD-10, the diagnosis code F16.7 corresponds most closely to the clinical picture. HPPD is rarely recognized amongst both hallucinogen users and psychiatrists, and is often misdiagnosed as a substance-induced psychosis.

Newer research makes a distinction between HPPD I and HPPD II.[3] The more drastic cases, as seen in HPPD II, are believed to be caused by the use of psychedelics as well as comorbid mental disorders.[3] Some people who have this disorder report that they developed symptoms of HPPD after their first use of such drugs (most notably LSD). Because research regarding HPPD is currently lacking, there is little information on effective treatments, its aetiology and relationship to other disorders, and precise mechanism.[7]

The mechanisms behind HPPD are still not well understood, and there is a lack of clear explanation regarding its causes. One of the current hypotheses suggests that anxiety may not only amplify existing visual disturbances but could also potentially trigger these visual phenomena. Many individuals with HPPD report that their visual distortions become more pronounced or even emerge during periods of heightened anxiety or stress. This indicates that anxiety may play a role in both the onset and intensification of these symptoms, making them more noticeable or cognitively magnifying the perception of such disturbances.

History

edit

In 1898, the English physician and intellectual Havelock Ellis reported a heightened sensitivity to what he described as "the more delicate phenomena of light and shade and color" for a prolonged period of time after he was exposed to the hallucinogenic drug mescaline. This may have been one of the first recorded symptoms of what would later be called HPPD.[8] Hallucinogen-persisting perception disorder was first described in 1954,[9] with other observations made in early psychedelic research.[10] Horowitz[11] first introduced the term flashbacks, referring to recurrent and spontaneous perceptual distortions and unbidden images. When these "flashbacks" present as recurrent, but without a current acute, or chronic hallucinogen intake, the disturbance is referred to as HPPD. Horowitz classified also three types of visual flashbacks: (a) perceptual distortions (e.g., seeing haloes around objects); (b) heightened imagery (e.g., visual experiences as much more vivid and dominant in one's thoughts); and (c) recurrent unbidden images (e.g., subjects see objects that are not there). LSD therapist Stanislav Grof noted an HPPD phenomenon in his book LSD Psychotherapy from 1978, which noted that "[l]ong after the pharmacological effect of the drug has subsided, the patient may still report anomalies in color-perception, blurred vision, after-images, spontaneous imagery, alterations in body image, intensification of hearing, ringing in the ears, or various strange physical feelings."

HPPD has been introduced under the diagnosis of Post-hallucinogen Perception Disorder in 1987 within the DSM-III-R.[12] Subsequently, the DSM-IV-TR[13] recognized the syndrome as Hallucinogen-Persisting Perception Disorder (Flashbacks) (code 292.89) (15). The Neurosensory Research Foundation[14] was founded by HPPD sufferers to promote research and awareness around the condition. Subsequently, in 2021, the Perception Restoration Foundation[15] was launched to bolster efforts for research, awareness and harm reduction. In 2022, journalists at Psymposia and New York Magazine revealed that a participant in MAPS' landmark MDMA trials for PTSD developed post-psychedelic visual effects similar to HPPD.[16][time needed] Subclinical HPPD phenomena have occurred in other trial settings.[17]

Symptoms

edit

Typical symptoms of the disorder include halos or auras surrounding objects, trails following objects in motion, difficulty distinguishing between colors, apparent shifts in the hue of a given item, the illusion of movement in a static setting, visual snow, distortions in the dimensions of a perceived object, intensified hypnagogic and hypnopompic hallucinations, monocular double vision, seeing an excessive amount of eye floaters, the morphing of multiple objects into one texture, and blue field entoptic phenomenon. The visual alterations experienced by those with HPPD are not homogeneous and there appear to be individual differences in both the number and intensity of symptoms.[18]

Visual aberrations can occur periodically in healthy individuals – e.g., afterimages after staring at a light, noticing floaters inside the eye, blue field entoptic phenomenon or seeing specks of light in a darkened room. However, in people with HPPD, symptoms seem typically to be worse, but complication comes from the additional roles played anxiety and fixation. Indeed, anxiety has been implicated in visual perceptual effects similar to HPPD,[19] and authors have recognized the crucial role of attending to underlying anxiety and panic in recovering from the disorder.

There is some uncertainty about to what degree visual snow constitutes a true HPPD symptom. There are individuals who have never used a drug which could have caused the onset, but yet experience the same grainy vision reported by those with HPPD, like people with the closely-linked neurological disorder known as visual snow syndrome.[20] There are a few potential reasons for this, the most obvious of which being the theory that the drug usage may exaggerate the intensity of visual snow. At the same time, beyond the characteristic visual snow symptom, there is considerable overlap between the conditions, including after-images, palinopsia, tinnitus, dissociation and free-floating anxiety, leading some to suggest that HPPD shares a strong relationship with visual snow syndrome.[21] Visual snow syndrome is defined as lacking any known cause and is specifically distinguished from HPPD in its nosology, yet further research may clarify the relationship. HPPD usually has a visual manifestation, but some hallucinogenic and psychiatric drugs affect the auditory sense and can produce tinnitus-like symptoms as a side effect, and there are many anecdotal reports of people getting tinnitus with their HPPD.[citation needed]

A significant number of those reporting HPPD also describe comorbid depersonalization-derealization and anxiety disorders.[1] Anxiety, PTSD [22][23] and panic[24] can promote depersonalization-derealization[25] and visual disturbances, and vice versa, so these features may run in multidirectional relationships. Abraham suggested that all three can arise from a broader mechanism of disinhibition in sensory perception, affect and sense-of-self occasioned by psychedelic experience. It is not uncommon for depersonalization-derealization to be the most distressing symptom of the condition.

According to a 2016 review, there are two theorized subtypes of the condition.[26][6] Type 1 HPPD is where people experience random, brief flashbacks.[6] Type 2 HPPD entails experiencing persistent changes to vision, which may vary in intensity.[6] This model has faced scrutiny, however, due to "flashbacks" often being considered a separate condition and not always a perceptual one.[7]

Causes

edit

A vast list of psychoactive substances has been identified and linked with the development of this condition, including lysergamides like LSD and LSA, tryptamines like psilocybin and DMT, phenethylamines like 2C-B, MDMA, MDA and mescaline.[27][3] Dissociatives such as ketamine and dextromethorphan as well as cannabis and synthetic cannabinoids, salvia divinorum, datura and iboga are also known to trigger HPPD.[3] It is therefore clear that HPPD is not strictly associated with psychedelic consumption as a number of hallucination-inducing substances may be correlated with its arising.[3] For some, the dosage and how frequently one uses these substances does not seem to matter in the development of this condition, since there are several reports in the literature where patients were diagnosed after a single use.[3] This strongly indicates that there may be a genetic predisposition to this condition. It also seems that combining recreational or medical drugs that act on the 5HT2-a receptors, like SSRIs, drastically increases the chances of developing HPPD due to the drug-drug interaction.[28] HPPD is not related to psychosis due to the fact people affected by the disorder can easily distinguish their visual disturbances from reality.[29] Which drugs are most prone to causing HPPD is not entirely known. While LSD has been described as the leading cause of HPPD, this may be a function of LSD's historically higher relative popularity as a recreational psychedelic drug.[1] Popularity effects may explain the high proportion of cases precipitated by cannabis. A 2022 clinical review found no significant difference in the induction of subclinical visual phenomena between MDMA, LSD and psilocybin.[17] Curiously, lasting visual effects have also occurred as complications of benzodiazepine withdrawal syndrome.[30]

Pathophysiology

edit

The exact pathophysiologic mechanism underlying HPPD is poorly understood. The primary neurobiological hypothesis is that persistent hallucinations are the result of chronic disinhibition of visual processors and subsequent dysfunction in the central nervous system following consumption of hallucinogens.[31][32] Chronic disinhibition may occur from destruction and/or dysfunction of cortical serotonergic inhibitory interneurons involving the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA).[33][34][35][36] This ultimately can cause disruption of the normal neurological mechanisms that are responsible for filtration of unnecessary stimuli in the brain. On a macroscopic level, the lateral geniculate nucleus (LGN) of the thalamus, which is important in visual processing, has also been implicated in the pathophysiology of HPPD.[37]

Other researchers have suggested HPPD may be related to drug-induced elevations in neuroplasticity[38] – an effect also noted to occur for SSRIs.[39] Reverse neuroplasticity effects may account for anecdotal reports of individuals treating their HPPD symptoms with further psychedelic drug use, while others report significant deterioriations in their symptoms.[citation needed]

Being characterized by clinical distress and impairment, however, HPPD is also shaped by psychosocial factors. There is tentative evidence that those who develop distressing HPPD have higher trait anxiety,[40] or experienced elevations in baseline anxiety from possibly negative psychedelic experiences.[26] Elevations in anxiety, and anxious responses to visual and related symptoms, may provoke direct elevations in symptom intensity and fuel the distress that defines HPPD as a clinical entity. Certain core beliefs and automatic thoughts are observed to occur among those reporting HPPD: fears of brain damage, a 'never-ending trip', the development of schizophrenia or a related psychosis spectrum disorder, a more generalized concern surrounding insanity, and destructive thoughts concerning the loss of one's previous self or a new identity centred on brokenness and alienation from others.[citation needed] Being a drug-related disorder, HPPD is therefore vulnerable to internalized anti-drug stigma, specifically around 'flashbacks' and 'brain frying', which were heavily propagandized in prohibitionist campaigns in the 20th-century.[41]

Treatment

edit

As of January 2022 there is no officially recognized cure or therapy for HPPD, but those affected with HPPD are heavily advised to discontinue all recreational drug use. Improving sleep quality, reducing anxiety, lowering screen use, improving diet quality and pursuing regular exercise are encouraged as general lifestyle changes. To decrease fixation and monitoring behaviors with visual symptoms, increased focus on external tasks may also be encouraged.[citation needed]

Antipsychotics such as aripiprazole or risperidone, intended to treat mental disorders like schizophrenia, should only be taken in careful consultation with a psychiatrist experienced in HPPD. The success rate of antipsychotics as a treatment method for HPPD is still debated. Two young men with HPPD and schizophrenia as a comorbidity experienced a remission of visual perceptual disturbance during a 6-month follow-up observation under treatment with risperidone.[42] There was a case study in 2013 where oral risperidone was also successful for treating HPPD.[43] In other cases risperidone has shown no effect on HPPD[42] or where it had a paradoxical effect and lead to permanent symptom exacerbation.[44]

  • Lamotrigine, an anticonvulsant, is the most popular medication for HPPD treatment. In the case of a 36-year-old man with HPPD for 18-years, the complex visual perception disorders largely resolved within 12 months after initiation of treatment with lamotrigine. In another case a 33-year-old woman developed HPPD after abusing LSD for a year long at the age of 18. She reported afterimages, perception of movement in her peripheral visual fields, blurring of small patterns, halo effects, and macro- and micropsia. Previous treatment with antidepressants and risperidone failed to ameliorate these symptoms. Upon commencing drug therapy with lamotrigine, these complex visual disturbances receded almost completely. There are also many anecdotal reports on lamotrigine alleviating some of the symptoms. Lamotrigine is considered a possible treatment option for HPPD. Lamotrigine is generally well tolerated with a relative lack of adverse effects.[45]
  • Clonidine, an antihypertensive, that a pilot study of eight patients suggested could help significantly alleviate "LSD-related flashbacks".[46]
  • In a case study of two subjects with synthetic cannabis-induced HPPD the symptoms significant improvement with clonazepam treatment.[47] In a 2003 study 16 people with LSD-induced HPPD reported a significant relief and the presence of only mild symptomatology during clonazepam administration. And as with lamotrigine, there are many anecdotal reports of clonazepam greatly decreasing symptoms at >1.5 mg doses[48]
  • Other medical drugs that people have reported some symptom reduction with are the anticonvulsants gabapentin, levetiracetam and valproic acid.

A 2022 case reported indicated promise for brain stimulation therapy for a longstanding HPPD patient.[49]

Outside of pharmacotherapy, recovery from HPPD as a clinical entity – that, is involving distress and impairment – can come about through psychological and social means. Case reports of psychotherapy for HPPD suggest that anxiety reduction, muscle relaxation, and re-framing one's visual phenomena through personal destigmatization and normalization may be helpful.[50][51][52][53] Some authors have suggested that HPPD be better designated as a particular somatic symptom disorder[5] rather than a disorder defined centrally by hallucinogen use. Cognitive behavioral therapy has shown promise for somatic symptom disorders,[54] as well as related distress from tinnitus. CBT has likewise shown promise for depersonalization-derealization disorder,[55] which occurs as a common comorbidity to HPPD and seems to share many of the same catastrophic thoughts.[56] The Perception Restoration Foundation hosts a Specialists Directory that lists professionals with prior experience or relevant expertise in helping those with HPPD.[57]

Prevalence

edit

In a 2010 optional online survey of psychedelic users seeking medical information, 60% reported recurring HPPD-like effects, though only 4.2% considered seeking treatment due to the severity. The authors concede occurrences are rare but suggest the survey supports a need for further research.[58] In a 2022 double-blind, placebo-controlled study, 142 subjects received LSD, psilocybin, or both, reported no cases of HPPD, and up to 9.2% of the subjects had flashbacks which were "transient, mostly experienced as benign and did not impair daily life".[17]

Society and culture

edit

In 1971, Shelagh McDonald vanished from the world of folk music after experiencing severe HPPD, losing contact with the entire industry until 2005.

In the second episode of the first season of the 2014 series True Detective ("Seeing Things"), primary character Rustin Cohle (Matthew McConaughey) is depicted as having symptoms similar to HPPD such as light tracers as a result of "neurological damage" from substance use.[59]

American journalist Andrew Callaghan, former host of the internet series All Gas No Brakes and current host of Channel 5, revealed during a 2021 interview with Vice News that he experiences the symptoms of HPPD as a result of psilocybin use at a young age. Describing his symptoms, he noted that he experiences persistent visual snow and palinopsia.[60]

American YouTuber and musician Matt Watson, known for cohosting the YouTube channel with over 1 million subscribers known as SuperMega, has revealed in a podcast interview with bbno$ that he acquired HPPD as a result of LSD use at the age of 22.[61] He stated that he experiences several persistent floaters in his vision, constant visual "static", and various other symptoms associated with HPPD.[citation needed]

Other disorders with similar symptoms

edit

It must be emphasized that individuals without HPPD will sometimes notice visual abnormalities. These include floaters (material floating in the eye fluid that appears as black/dark objects floating in front of the eyes and are particularly visible when looking at the bright sky or on a white wall) and the white blood cells of the retinal blood vessels (seen as tiny, fast-moving and quickly disappearing white specks). Likewise, bright lights in an otherwise dark environment may generate trails and halos. Most people don't notice these effects, because they are so used to them. A person fearful of having acquired HPPD may be much more conscious about any visual disturbance, including those that are normal. In addition, visual problems can be caused by brain infections or lesions, epilepsy, and a number of mental disorders (e.g., anxiety, delirium, dementia, schizophrenia, Parkinson's disease). For an individual to be diagnosed with HPPD, these other potential causes must be ruled out.

References

edit
  1. ^ a b c Vis PJ, Goudriaan AE, Ter Meulen BC, Blom JD (2021). "On Perception and Consciousness in HPPD: A Systematic Review". Frontiers in Neuroscience. 15: 675768. doi:10.3389/fnins.2021.675768. PMC 8385145. PMID 34456666.
  2. ^ "New Study: Antidepressants, Vision Problems, & VSS!". 20 March 2022.
  3. ^ a b c d e f g h Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, et al. (March 2018). "Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives". Brain Sciences. 8 (3): 47. doi:10.3390/brainsci8030047. PMC 5870365. PMID 29547576.
  4. ^ Zobor D, Strasser T, Zobor G, Schober F, Messias A, Strauss O, et al. (April 2015). "Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect?". Documenta Ophthalmologica. Advances in Ophthalmology. 130 (2): 121–130. doi:10.1007/s10633-015-9481-2. PMID 25612939. S2CID 9684212.
  5. ^ a b Krebs TS, Johansen PØ (19 August 2013). "Psychedelics and mental health: a population study". PLOS ONE. 8 (8): e63972. Bibcode:2013PLoSO...863972K. doi:10.1371/journal.pone.0063972. PMC 3747247. PMID 23976938.
  6. ^ a b c d e Halpern JH, Lerner AG, Passie T (2016). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 333–360. doi:10.1007/7854_2016_457. ISBN 978-3-662-55878-2. PMID 27822679.
  7. ^ a b Halpern JH, Pope HG (March 2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–119. doi:10.1016/s0376-8716(02)00306-x. PMID 12609692.
  8. ^ Hanson D (29 April 2013). "When the Trip Never Ends". Dana Foundation.
  9. ^ Sandison RA, Spencer AM, Whitelaw JD (April 1954). "The therapeutic value of lysergic acid diethylamide in mental illness". The Journal of Mental Science. 100 (419): 491–507. doi:10.1192/bjp.100.419.491. PMID 13175011.
  10. ^ Robbins E, Frosch WA, Stern M (September 1967). "Further observations on untoward reactions to LSD". The American Journal of Psychiatry. 124 (3): 393–395. doi:10.1176/ajp.124.3.393. PMID 6066637.
  11. ^ Horowitz MJ (October 1969). "Flashbacks: recurrent intrusive images after the use of LSD". The American Journal of Psychiatry. 126 (4): 565–569. doi:10.1176/ajp.126.4.565. PMID 5806803.
  12. ^ American Psychiatric Association. DSM III-R. Diagnostic and Statistical Manual of Mental Disorders––Third Revised Version. Arlington: American Psychiatric Association Publishing (1987).
  13. ^ American Psychiatric Association. DSM IV-TR. Diagnostic and Statistical Manual of Mental Disorders––Forth Text Revised Version. Arlington: American Psychiatric Association Publishing (2000).
  14. ^ "The Neurosensory Research Foundation (NRF)".
  15. ^ "Perception Restoration Foundation".
  16. ^ "A Power Trip Refresher". The Cut. 16 March 2022.
  17. ^ a b c Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, et al. (June 2022). "Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants". Psychopharmacology. 239 (6): 1933–1943. doi:10.1007/s00213-022-06066-z. PMC 9166883. PMID 35076721.
  18. ^ Abraham HD (August 1983). "Visual phenomenology of the LSD flashback". Archives of General Psychiatry. 40 (8): 884–889. doi:10.1001/archpsyc.1983.01790070074009. PMID 6135405.
  19. ^ Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013). "Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm". Psychology, Health & Medicine. 18 (3): 363–374. doi:10.1080/13548506.2012.722649. PMID 23186162. S2CID 39115198.
  20. ^ "Visual Snow Initiative".
  21. ^ "Visual Snow Syndrome". National Organization for Rare Disorders, Inc.
  22. ^ "Exhibit 1.3-4, DSM-5 Diagnostic Criteria for PTSD". Treatment Improvement Protocol (TIP) Series, No. 57. Center for Substance Abuse Treatment (US). Trauma-Informed Care in Behavioral Health Services. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2014.
  23. ^ Trachtman JN (May 2010). "Post-traumatic stress disorder and vision". Optometry. 81 (5). St. Louis, Mo.: 240–52. doi:10.1016/j.optm.2009.07.017. PMID 20435270.
  24. ^ "Table 3.10, Panic Disorder and Agoraphobia Criteria Changes from DSM-IV to DSM-5". Treatment Improvement Protocol (TIP) Series, No. 57. Center for Substance Abuse Treatment (US). Trauma-Informed Care in Behavioral Health Services. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2016.
  25. ^ Simeon D, Kozin DS, Segal K, Lerch B, Dujour R, Giesbrecht T (January 2008). "De-constructing depersonalization: further evidence for symptom clusters". Psychiatry Research. 157 (1–3): 303–306. doi:10.1016/j.psychres.2007.07.007. PMID 17959254. S2CID 10610680.
  26. ^ a b Halpern JH, Lerner AG, Passie T (2018). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Current Topics in Behavioral Neurosciences. 36: 333–360. doi:10.1007/7854_2016_457. ISBN 978-3-662-55878-2. PMID 27822679.
  27. ^ Majić T, Schmidt TT, Hermle L (2016). "Flashbacks und anhaltende Wahrnehmungsstörungen nach Einnahme von serotonergen Halluzinogenen". Handbuch Psychoaktive Substanzen [Flashbacks and persistent perceptual disturbances after ingestion of serotonergic hallucinogens] (in German). pp. 1–13. doi:10.1007/978-3-642-55214-4_63-1. ISBN 978-3-642-55214-4.
  28. ^ Hosanagar A, Cusimano J, Radhakrishnan R (February 2021). "Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence". The Journal of Clinical Psychiatry. 82 (3). doi:10.4088/JCP.20ac13787. PMID 33988930. S2CID 233974724.
  29. ^ Bogenschutz MP, Ross S (2016). "Therapeutic Applications of Classic Hallucinogens". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 361–391. doi:10.1007/7854_2016_464. ISBN 978-3-662-55878-2. PMID 28512684.
  30. ^ Mintzer MZ, Stoller KB, Griffiths RR (November 1999). "A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users". Psychopharmacology. 147 (2): 200–209. doi:10.1007/s002130051161. PMID 10591888. S2CID 35666163.
  31. ^ Abraham HD, Aldridge AM (October 1993). "Adverse consequences of lysergic acid diethylamide". Addiction. 88 (10): 1327–1334. doi:10.1111/j.1360-0443.1993.tb02018.x. PMID 8251869.
  32. ^ G Lerner A, Rudinski D, Bor O, Goodman C (2014). "Flashbacks and HPPD: A Clinical-oriented Concise Review" (PDF). The Israel Journal of Psychiatry and Related Sciences. 51 (4): 296–301. PMID 25841228.
  33. ^ Abraham HD, Duffy FH (October 1996). "Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition". Psychiatry Research. 67 (3): 173–187. doi:10.1016/0925-4927(96)02833-8. PMID 8912957. S2CID 7587687.
  34. ^ Abraham HD, Duffy FH (October 2001). "EEG coherence in post-LSD visual hallucinations". Psychiatry Research. 107 (3): 151–163. doi:10.1016/S0925-4927(01)00098-1. PMID 11566431. S2CID 14509310.
  35. ^ Garratt JC, Alreja M, Aghajanian GK (February 1993). "LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons". Synapse. 13 (2): 123–134. doi:10.1002/syn.890130205. PMID 8446921. S2CID 9496153.
  36. ^ Sanders-Bush E, Burris KD, Knoth K (September 1988). "Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis". The Journal of Pharmacology and Experimental Therapeutics. 246 (3): 924–928. PMID 2843634.
  37. ^ Schankin CJ, Maniyar FH, Sprenger T, Chou DE, Eller M, Goadsby PJ (June 2014). "The relation between migraine, typical migraine aura and "visual snow"". Headache. 54 (6): 957–966. doi:10.1111/head.12378. PMID 24816400. S2CID 4164884.
  38. ^ Calder AE, Hasler G (January 2023). "Towards an understanding of psychedelic-induced neuroplasticity". Neuropsychopharmacology. 48 (1): 104–112. doi:10.1038/s41386-022-01389-z. PMC 9700802. PMID 36123427.
  39. ^ Reed MB, Vanicek T, Seiger R, Klöbl M, Spurny B, Handschuh P, et al. (August 2021). "Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval". NeuroImage. 236: 118039. doi:10.1016/j.neuroimage.2021.118039. PMC 7610799. PMID 33852940.
  40. ^ Irvine A, Luke D (September 2022). "Apophenia, absorption and anxiety: Evidence for individual differences in positive and negative experiences of Hallucinogen Persisting Perceptual Disorder" (PDF). Journal of Psychedelic Studies. 6 (2): 88–103. doi:10.1556/2054.2022.00195. S2CID 251461094.
  41. ^ Bracco JM (2019). "The United States Print Media and its War on Psychedelic Research in the 1960s". The Exposition. 5 (1): 2.
  42. ^ a b Hermle L, Ruchsow M, Täschner KL (September 2015). "[Hallucinogen Persisting Perception Disorder (HPPD) and Flashback Phenomena – Differential Diagnosis and Explanation Models]". Fortschritte der Neurologie-Psychiatrie. 83 (9): 506–515. doi:10.1055/s-0035-1553717. PMID 26421858.
  43. ^ Subramanian N, Doran M (March 2014). "Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report". Irish Journal of Psychological Medicine. 31 (1): 47–49. doi:10.1017/ipm.2013.59. PMID 30189471. S2CID 52170294.
  44. ^ Abraham HD, Mamen A (June 1996). "LSD-like panic from risperidone in post-LSD visual disorder". Journal of Clinical Psychopharmacology. 16 (3): 238–241. doi:10.1097/00004714-199606000-00008. PMID 8784656.
  45. ^ Hermle L, Simon M, Ruchsow M, Geppert M (October 2012). "Hallucinogen-persisting perception disorder". Therapeutic Advances in Psychopharmacology. 2 (5): 199–205. doi:10.1177/2045125312451270. PMC 3736944. PMID 23983976.
  46. ^ Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A (January 2000). "LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study". International Clinical Psychopharmacology. 15 (1): 35–37. doi:10.1097/00004850-200015010-00005. PMID 10836284. S2CID 10871755.
  47. ^ G Lerner A, Goodman C, Bor O, Lev-Ran S (2014). "Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports" (PDF). The Israel Journal of Psychiatry and Related Sciences. 51 (4): 277–280. PMID 25841224.
  48. ^ Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A (March 2003). "Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features". International Clinical Psychopharmacology. 18 (2): 101–105. doi:10.1097/00004850-200303000-00007. PMID 12598822. S2CID 24924089.
  49. ^ Haslacher D, Novkovic N, Buthut M, Heinz A, Soekadar SR (2022). "Pathological Delta Oscillations in Hallucinogen Persisting Perception Disorder: A Case Report". Frontiers in Psychiatry. 13: 867314. doi:10.3389/fpsyt.2022.867314. PMC 8987195. PMID 35401281.
  50. ^ Matefy RE (April 1973). "Behavior therapy to extinguish spontaneous recurrences of LSD effects: a case study". The Journal of Nervous and Mental Disease. 156 (4): 226–231. doi:10.1097/00005053-197304000-00002. PMID 4708882. S2CID 9341528., Spevack M, Pihl R, Rowan T (April 1973). "Behavior therapies in the treatment of drug abuse: Some case studies". The Psychological Record. 23 (2): 179–184. doi:10.1007/BF03394152. S2CID 149221411.
  51. ^ Stott R (2009). "Tripping into trauma: Cognitive-behavioural treatment for a traumatic stress reaction following recreational drug use.". In Grey N (ed.). A casebook of cognitive therapy for traumatic stress reactions. Routledge/Taylor & Francis Group. pp. 49–60.
  52. ^ Ezzamel S, Spada MM, Nikčević AV (2015). "Cognitive-behavioural case formulation in the treatment of a complex case of social anxiety disorder and substance misuse.". In Bruch M (ed.). Beyond diagnosis: case formulation in cognitive behavioural therapy (2nd ed.). Chichester, U.K.: Wiley Blackwell. pp. 194–219. ISBN 9781119960768.
  53. ^ Genova P (2002). "Introduction to Part II". The thaw : reclaiming the person for psychiatry (2nd, rev. & expanded ed.). Hillsdale, NJ: Analytic Press. doi:10.4324/9780203767238. ISBN 978-0-203-76723-8.
  54. ^ Orzechowska A, Maruszewska P, Gałecki P (July 2021). "Cognitive Behavioral Therapy of Patients with Somatic Symptoms-Diagnostic and Therapeutic Difficulties". Journal of Clinical Medicine. 10 (14): 3159. doi:10.3390/jcm10143159. PMC 8307926. PMID 34300324.
  55. ^ Hunter EC, Baker D, Phillips ML, Sierra M, David AS (September 2005). "Cognitive-behaviour therapy for depersonalisation disorder: an open study". Behaviour Research and Therapy. 43 (9): 1121–1130. doi:10.1016/j.brat.2004.08.003. PMID 16005701.
  56. ^ Hunter EC, Phillips ML, Chalder T, Sierra M, David AS (December 2003). "Depersonalisation disorder: a cognitive-behavioural conceptualisation". Behaviour Research and Therapy. 41 (12): 1451–1467. doi:10.1016/s0005-7967(03)00066-4. PMID 14583413.
  57. ^ "Specialists Directory". The Perception Restoration Foundation.
  58. ^ Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (March 2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. PMID 21035275.
  59. ^ Fukunaga CJ, Cuddy C, Pizzolatto N, McConaughey M, Harrelson W, Monaghan M, Potts M, Arkapaw A, Hall A, Burnett TB (2016). True detective. Season 1, Season 1. OCLC 964500128.[non-primary source needed]
  60. ^ Documenting America's Underbelly - ALL GAS NO BRAKES (video). Vice. January 21, 2021. 20:48-21:49 minutes in. Archived from the original on 2021-12-13. Retrieved January 24, 2021.
  61. ^ SuperMegaCast - EP 324: Ram Ranch (ft. bbno$) (video). SuperMega. December 4, 2022. 57:08-58:00 minutes in. Archived from the original on 2023-01-26. Retrieved January 25, 2023.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hallucinogen_persisting_perception_disorder&oldid=1251266950"